Name: Latest research reports of Dr. Reddy's Laboratories Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Dr. Reddy's Laboratories Ltd.
Rating: 3
Author: Motilal Oswal

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	13 Sep 2025	Dr. Reddy's Labs	Consensus Share Price Target	1316.70	1287.37	-	-2.23	hold	pdf Detailed Estimates
	11 May 2023	Dr. Reddy's Labs	Motilal Oswal Reco Target	1316.70	4500.00	4532.00 (-70.95%)	Target met	Neutral	pdf post cache	Broker Report Earnings growth to moderate after superior show in FY23 Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	11 May 2023	Dr. Reddy's Labs	SMC online	1316.70		4532.00 (-70.95%)	Pre-Bonus/ Split	Results Update	pdf post cache	Broker Report Dr. Reddys Laboratories SMC online pdf Copy Link Share on Share on Share on Share on Alert
	11 May 2023	Dr. Reddy's Labs	Prabhudas Lilladhar Reco Target	1316.70	4500.00	4532.00 (-70.95%)	Target met	Sell	pdf post cache	Broker Report DR REDDY'S LABS Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	11 May 2023	Dr. Reddy's Labs	BOB Capital Markets Ltd. Target	1316.70	4900.00	4532.00 (-70.95%)	Target met	Hold	pdf post cache	Broker Report Dr Reddy's Labs (HOLD): Core business remains sluggish BOB Capital Markets Ltd. Q4 broadly in line as revenue/EBITDA grew 16%/35% YoY (-7%/-23% QoQ), albeit aided by one-offs pdf Copy Link Share on Share on Share on Share on Alert
	07 Feb 2023	Dr. Reddy's Labs	Geojit BNP Paribas Target	1316.70	5166.00	4440.25 (-70.35%)	Target met	Buy	pdf post cache	Broker Report DR. REDDY'S LABORATARIES Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	27 Jan 2023	Dr. Reddy's Labs	ICICI Direct Target	1316.70	5210.00	4314.00 (-69.48%)	Target met	Buy	pdf post cache	Broker Report Dr Reddy's Laboratories ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	27 Jan 2023	Dr. Reddy's Labs	Axis Direct Target	1316.70	5100.00	4314.00 (-69.48%)	Target met	Buy	pdf post cache	Broker Report Result Update:Dr Reddys Labs Axis Direct We recommend a BUY on the stock. pdf Copy Link Share on Share on Share on Share on Alert
	27 Jan 2023	Dr. Reddy's Labs	ICICI Securities Limited Target	1316.70	5131.00	4200.95 (-68.66%)	Target met	Buy	pdf post cache	Broker Report Revlimid springs a surprise, again! ICICI Securities Limited Dr. Reddy’s Laboratories’ (DRL) Q3FY23 reported performance exceeded our and consensus estimates, largely driven by higher-than-estimated sales of Revlimid in Q3FY23. This resulted in 27.3% YoY growth in revenue to Rs67.7bn (I-Sec: Rs58.6bn). pdf Copy Link Share on Share on Share on Share on Alert
	26 Jan 2023	Dr. Reddy's Labs	BOB Capital Markets Ltd. Target	1316.70	4700.00	4200.95 (-68.66%)	Target met	Hold	pdf post cache	Broker Report Dr Reddy's Labs (HOLD): Strong US sales; recovery in EM and PSAI businesses BOB Capital Markets Ltd. Q3 revenue growth strong at 27% YoY to Rs 67.7bn, supported by US contribution and launches pdf Copy Link Share on Share on Share on Share on Alert
	26 Dec 2022	Dr. Reddy's Labs	Axis Direct Target	1316.70	4750.00	4248.60 (-69.01%)	Target met	Buy	pdf post cache	Broker Report Pick of the Week:26 DEC 2022 Axis Direct We recommend a BUY rating on the stock with a target price of Rs 4,750/share, implying an upside of 10% from the CMP. pdf Copy Link Share on Share on Share on Share on Alert
more loading

29.09% Gain from 52W Low

Dr. Reddy's Laboratories Ltd. share price target

Dr. Reddy's Laboratories Ltd. has an average share price target of 1278.56. The consensus estimate represents a downside of -2.90% from the last price of 1316.70. View 18 reports from 9 analysts offering long-term price targets for Dr. Reddy's Laboratories Ltd..

Earnings growth to moderate after superior show in FY23

Dr. Reddys Laboratories

DR REDDY'S LABS

Dr Reddy's Labs (HOLD): Core business remains sluggish

DR. REDDY'S LABORATARIES

Dr Reddy's Laboratories

Result Update:Dr Reddys Labs

Revlimid springs a surprise, again!

Dr Reddy's Labs (HOLD): Strong US sales; recovery in EM and PSAI businesses

Pick of the Week:26 DEC 2022

Advisor Screeners